Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 14655. Отображено 100.
05-01-2012 дата публикации

Hemostatic fibrous material

Номер: US20120004636A1
Автор: Denny Lo
Принадлежит: Denny Lo

This disclosure relates to devices for promoting the clotting of blood in human beings or animals, or hemostatic devices. These devices may comprise a fibrous material or materials comprising one or more fibers such as a gauze or a cloth. Some of the fibers in these materials or devices may comprise a macromolecular material and a hemostatic hemostatic additive material such as kaolin or another clay.

Подробнее
26-01-2012 дата публикации

Process for making dry and stable hemostatic compositions

Номер: US20120021058A1
Автор: Andreas Goessl

Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a dry granular preparation of a biocompatible polymer suitable for use in hemostasis, b) coating the granules in said dry granular preparation with a preparation of a coagulation inducing agent, thereby obtaining coagulation inducing agent coated polymer granules, c) filling said coagulation inducing agent coated polymer granules into a final container, d) finishing the final container to a storable pharmaceutical device containing said coagulation inducing agent coated polymer granules as a dry and stable hemostatic composition.

Подробнее
26-01-2012 дата публикации

Bone cement system for bone augmentation

Номер: US20120022542A1
Принадлежит: Synthes USA LLC

A bone cement is provided that includes a solid component and a liquid component. The solid component and liquid component are mixed together to form the bone cement. After completion of the solid and liquid component mixing, the bone cement has an initial viscosity effective for manual application or manual injection onto or into a targeted anatomical location, e.g., bone, and the cement has stable viscosity range that over both time and temperature is effective for uniformly filling the targeted anatomical location, for example an osteoporotic bone or a fractured vertebral body, with minimal to no leakage of the cement from the targeted anatomical location. Additionally, both the initial viscosity and the stable viscosity of the bone cement are within a range that renders the bone cement effective for injection with a manually operated syringe or multiple syringes.

Подробнее
02-02-2012 дата публикации

Thermoreversible collagen

Номер: US20120027732A1
Принадлежит: PURDUE RESEARCH FOUNDATION

This invention relates to collagen formulations. More particularly, this invention relates to thermoreversible collagen formulations and methods of their use and preparation.

Подробнее
02-02-2012 дата публикации

Fracture fixation systems

Номер: US20120029102A1
Принадлежит: Individual

Systems for bone fracture repair are disclosed. One system includes a biocompatible putty that may be packed about a bone fracture to provide full loadbearing capabilities within days. The disclosed putties create an osteoconductive scaffold for bone regeneration and degrade over time to harmless 5 resorbable byproducts. Fixation devices for contacting an endosteal wall of an intramedullary (IM) canal of a fractured bone are also disclosed. One such fixation device includes a woven elongated structure fabricated from resorbable polymer filaments. The woven elongated structure has resilient properties that allow the woven 10 structure to be radially compressed and delivered to the IM canal using an insertion tube. When the insertion tube is removed, the woven structure expands towards its relaxed cross-sectional width to engage the endosteal wall. The woven elongated structure is impregnated with a resorbable polymer resin that cures in situ, or in the IM canal.

Подробнее
02-02-2012 дата публикации

Osteoarthritis treatment and device

Номер: US20120029522A1
Принадлежит: Knee Creations LLC

A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and/or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.

Подробнее
09-02-2012 дата публикации

Bone cement composition, bone cement composition kit and forming method of bone cement hardened material

Номер: US20120035296A1
Принадлежит: Ishihara Sangyo Kaisha Ltd, KYOTO UNIVERSITY

The invention has as its objects the provision of a bone cement composition, a bone cement composition kit for obtaining the bone cement composition, and a production method of a bone cement hardened material, which are short in doughing time that is a time required to become a state in which a good handling operation can be conducted, and have consequently capable of achieving a high working efficiency by shortening the time required before the handling operation is started. The bone cement composition of the invention contains large-diameter (meth)acrylate polymer particles having an average particle diameter of 10 to 60 μm, small-diameter (meth)acrylate polymer particles having an average particle diameter of 0.1 to 2.0 μm, a (meth)acrylate monomer and a polymerization initiator, wherein the content of the small-diameter (meth)acrylate polymer particles is 5 to 30% by mass based on the total mass of the small-diameter (meth)acrylate polymer particles and the large-diameter (meth)acrylate polymer particles.

Подробнее
09-02-2012 дата публикации

Osteoarthritis treatment and device

Номер: US20120035609A1
Принадлежит: Knee Creations LLC

A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and/or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.

Подробнее
16-02-2012 дата публикации

Biologic treatment system and method

Номер: US20120041418A1
Автор: Thomas Q. Dinh
Принадлежит: AMS Research LLC

A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Подробнее
15-03-2012 дата публикации

Degradable hemostatic sponge and extrusion system and method for manufacturing the same

Номер: US20120065604A1
Принадлежит: Bioeconeer Inc

A degradable hemostatic sponge that can be self-degraded and absorbed by a human body has poly lactic acid as its main material and mixed with a moisture-absorbent material, such as collagen, chitosan, starch and the like, at a specific ratio. Given grinding, mixing and melting steps, the materials using a supercritical fluid as a foaming agent can be used to manufacture the degradable hemostatic sponge having an open-cell microcellular form by a continuous extrusion foaming process. In addition, the present invention also includes a system and a method for manufacturing the degradable hemostatic sponge.

Подробнее
29-03-2012 дата публикации

Applicators for patches and adhesives

Номер: US20120078293A1

Apparatus is provided for use with a tubular structure ( 2 ) in a body of a patient. The apparatus includes an adhesive including first and second components, a container ( 27 ), one or more patches ( 3 ), and an applicator ( 1 ). The container ( 27 ) contains the first component of the adhesive and not the second component of the adhesive. The one or more patches ( 3 ) include the second component of the adhesive and not the first component of the adhesive. The applicator ( 1 ) is configured to removably hold the one or more patches ( 3 ), and to place the one or more patches ( 3 ) at least partially around the tubular structure ( 2 ). Other embodiments are also described.

Подробнее
05-04-2012 дата публикации

Apparatus and method for delivery of biological sealant

Номер: US20120083828A1
Принадлежит: Spinal Restoration Inc

A device for delivery of biologic materials, comprising: a cartridge having at least two cylinder bores for fluids to be delivered, wherein each cylinder includes an exit port for a fluid, a plunger within each cylinder for pushing the fluids out of the cylinder, a housing adapted to receive the cartridge, wherein the housing or cartridge includes an adaptor to receive and lock a manifold that operably connects to the exit ports of the cartridge, at least two toothed rams, wherein each toothed ram is at least partially within a cylinder bore, a trigger connected to the housing, wherein the trigger includes a toothed drive rack, a toothed wheel assembly that cooperates with the toothed drive rack and with the toothed rams, as well as methods of making the device, methods of using the device to treat discs, kits including the device.

Подробнее
19-04-2012 дата публикации

Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration

Номер: US20120093914A1
Принадлежит: MOMA THERAPEUTICS

In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens. The matrix can contain other effector molecules designed to attract specific cells to the matrix. The cells can be released from the matrix as the matrix degrades or by active migration from the matrix. The cells can also remain in the matrix and secret molecules such as proteins and hormones that will diffuse through the matrix material to the surrounding tissue.

Подробнее
26-04-2012 дата публикации

Porous vascular closure plug with starch powder

Номер: US20120101519A1
Принадлежит: Boston Scientific Scimed Inc

The disclosure provides a composite plug for vascular closure including a hemostatic material, and a method of manufacturing the composite plug including a hemostatic material. The composite plug may comprise one or more materials having varying porosity, density, or composition, and may include a powdered hemostatic material.

Подробнее
10-05-2012 дата публикации

Joint device and method

Номер: US20120116523A1
Автор: Peter Forsell
Принадлежит: MILUX HOLDING SA

A mould adapted to be introduced into a joint of a human patient for resurfacing at least one carrying contacting surface of said joint is provided. The mould is adapted to receive material for resurfacing at least one carrying contacting surface of said joint. The mould is further adapted to be resorbed by the human body or melt after having served its purpose. Further, a method of treating hip joint osteoarthritis in a human patient by providing an artificial hip joint surface using a mould is provided. The method comprises the steps of: said mould being placed inside of said hip joint, said mould being injected with a fluid adapted to harden, said fluid hardening inside of said hip joint, said mould being resorbed by the human body, and said hardened fluid serving as artificial hip joint surface.

Подробнее
17-05-2012 дата публикации

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Номер: US20120123557A1
Принадлежит: Edwards Lifesciences Corp

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Подробнее
24-05-2012 дата публикации

Modified hyaluronic acid polymer compositions and related methods

Номер: US20120128741A1
Принадлежит: Carbylan Biosurgery Inc

The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.

Подробнее
24-05-2012 дата публикации

Preparation of bone cement compositions

Номер: US20120129761A1
Принадлежит: Bone Support AB

A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising a) providing a bone cement powder comprising calcium sulfate hemihydrate, an accelerator for the hardening of the calcium sulfate hemihydrate by hydration, said accelerator being selected from the group consisting of saline and calcium sulfate dihydrate, and a powdered calcium phosphate component b) mixing the bone cement powder with the aqueous liquid for a period of time c) leaving the mixture for the time needed for allowing the hydration reaction of the calcium sulfate hemihydrate to proceed and allowing calcium sulfate dihydrate crystals to form and grow, and d) admixing the additive by means of a short-duration mixing using a minimum of energy surprisingly shortens the setting times for the cement comprising the additive that retard the setting process to the level observed in the absence of the additive and enables a complete hydration of calcium sulfate hemihydrate to calcium sulfate dihydrate, even when using additives else preventing the hardening.

Подробнее
24-05-2012 дата публикации

Clay-based hemostatic agents and devices for the delivery thereof

Номер: US20120130296A1
Принадлежит: Z Medica LLC

A hemostatic device for promoting the dotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Подробнее
07-06-2012 дата публикации

Umbilical cord amniotic membrane products

Номер: US20120141595A1
Принадлежит: TissueTech Inc

Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.

Подробнее
14-06-2012 дата публикации

Solid dressing for treating wounded tissue

Номер: US20120150087A1
Принадлежит: Dawson Beall, MACPHEE Martin

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Подробнее
28-06-2012 дата публикации

Compositions and methods for tissue filling and regeneration

Номер: US20120165935A1
Автор: Dennis E. Van Epps
Принадлежит: Allergan Inc

Injectable compositions are provided which include both a living cellular component and a filler component conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration.

Подробнее
19-07-2012 дата публикации

Low viscosity liquid polymeric delivery system

Номер: US20120183629A1
Автор: Richard L. Dunn
Принадлежит: DUNN RES AND CONSULTING LLC

Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a biodegradable liquid polymer implant are provided.

Подробнее
26-07-2012 дата публикации

Novel injectable chitosan mixtures forming hydrogels

Номер: US20120189704A1
Принадлежит: Chi2Gel Ltd

A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

Подробнее
26-07-2012 дата публикации

Compositions and improved soft tissue replacement methods

Номер: US20120189708A1
Принадлежит: Allergan Inc

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Подробнее
02-08-2012 дата публикации

Injectible, biocompatible synthetic bone growth composition

Номер: US20120195982A1

An injectible, biocompatible synthetic bone growth composition comprising a mineralized collagen and a calcium sulfate component. The composition is formed into injectible formulation that may be provided at the site of a skeletal defect via minimally invasive manner. An osteoinductive component may be further added, either before or after forming the unitary article. The composition may be formulated as a paste or putty and facilitates bone growth and/or repair.

Подробнее
18-10-2012 дата публикации

Implantable polymer for bone and vascular lesions

Номер: US20120263797A1
Принадлежит: BIOS2 Medical Inc

A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures.

Подробнее
18-10-2012 дата публикации

In-Situ Forming Foams for Treatment of Aneurysms

Номер: US20120265287A1
Принадлежит: Arsenal Medical Inc

Systems, methods and kits relating to in-situ forming polymer foams for the treatment of aneurysms are disclosed. The systems include an insertable medical device and an in-situ forming foam that is formed from a polymer that reacts in an aqueous environment. When used to treat an aneurysm, the foam is placed into contact with at least a portion of an exterior surface of the medical device and/or the tissue surface of the aneurysm.

Подробнее
25-10-2012 дата публикации

Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices

Номер: US20120270810A1
Принадлежит: Lifebond Ltd

Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.

Подробнее
20-12-2012 дата публикации

Clay-based hemostatic agents and devices for the delivery thereof

Номер: US20120321691A1
Принадлежит: Z Medica LLC

A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate.

Подробнее
10-01-2013 дата публикации

Injectable cross-linked hydrogels for biomaterial applications

Номер: US20130012913A1
Принадлежит: DREXEL UNIVERSITY, Synthes USA LLC

An injectable hydrogel composition comprising: water; and poly(vinyl alcohol) chemically cross-linked with a second polymer to form a cross-linked resin, wherein the second polymer is selected from the group consisting of: a polyhydric alcohol compound, a polyvalent epoxy compound, a polyvalent amine compound, a dialdehyde compound, a diisocyanate compound, and mixtures thereof, wherein the cross-linked resin has a degree of cross-linking of from about 0.0001 mol/mL to about 0.002 mol/mL, and wherein the hydrogel is flowable when heated above its melting point.

Подробнее
31-01-2013 дата публикации

Hemostatic sponge

Номер: US20130028975A1

The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both.

Подробнее
07-02-2013 дата публикации

Subchondral treatment of joint pain of the spine

Номер: US20130035761A1
Принадлежит: Knee Creations LLC

Methods for altering the natural history of degenerative disc disease and osteoarthritis of the spine are proposed. The methods focus on the prevention, or delayed onset or progression of, subchondral defects such as bone marrow edema or bone marrow lesion, and subchondral treatment to prevent the progression of osteoarthritis or degenerative disc disease in the spine and thereby treat pain.

Подробнее
14-02-2013 дата публикации

Collagen pad

Номер: US20130040885A1
Принадлежит: Tissue Science Laboratories Ltd

The present invention relates to a collagen pad and to processes for the manufacture thereof. One aspect of the invention provides a process for the manufacture of a collagen pad from a plurality of collagen particles, said process comprising steps of forming a dispersion of the collagen particles in an aqueous acid solution; and adding a flocculating agent to the dispersion to form a collagen floe. A further aspect of the invention provides a process for the manufacture of a collagen pad, wherein said process comprises a step of centrifuging the product of a flocculation reaction, said flocculation reaction comprising adding a flocculating agent to a dispersion of collagen particles in an aqueous acid solution to form a collagen floe. The collagen pad may be used, for example, in wound care.

Подробнее
21-02-2013 дата публикации

Polysaccharide Based Hydrogels

Номер: US20130045182A1
Принадлежит: Individual

Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

Подробнее
28-03-2013 дата публикации

Hemostatic sponge

Номер: US20130079695A1
Принадлежит: Z Medica LLC

A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Подробнее
18-04-2013 дата публикации

Dermal filler compositions

Номер: US20130096081A1
Принадлежит: Allergan Inc

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.

Подробнее
18-04-2013 дата публикации

Method of forming hemostatic products

Номер: US20130096479A1
Принадлежит: St Teresa Medical Inc

A hemostatic product having a plurality of hemostatic layers. Each of the hemostatic layers includes a dextran support and at least one hemostatic agent, which is selected from the group consisting of thrombin and fibrinogen. The hemostatic layers are arranged in a stacked configuration.

Подробнее
09-05-2013 дата публикации

Methods of making hyaluronic acid/collagen compositions

Номер: US20130116411A1
Принадлежит: Allergan Inc

Hyaluronic acid and collagen may be crosslinked in aqueous solution as described herein. The crosslinked macromolecular matrices obtained in this process may be used as a hydrogel for implants and fillers for human aesthetic and therapeutic products.

Подробнее
16-05-2013 дата публикации

Compositions for Regenerating Defective or Absent Myocardium

Номер: US20130123176A1
Автор: Robert G. Matheny
Принадлежит: Individual

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Подробнее
16-05-2013 дата публикации

Modified starch material of biocompatible hemostasis

Номер: US20130123213A1
Автор: CHENG Xing, Xin Ji, Xueshen Shi
Принадлежит: Individual

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Подробнее
13-06-2013 дата публикации

Thrombin-free biological adhesive and use thereof as a medicament

Номер: US20130149292A1
Автор: Abdessatar Chtourou
Принадлежит: LFB SA

The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Подробнее
13-06-2013 дата публикации

Muscle-based grafts/implants

Номер: US20130149356A1
Принадлежит: RTI Biologics Inc

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic agent to attract a desired cell.

Подробнее
13-06-2013 дата публикации

Hemostasis Composition with Magnetite

Номер: US20130150652A1
Принадлежит: Biolife LLC

A composition and method of arresting the flow of blood from a bleeding wound. The composition preferably includes an anhydrous salt ferrate compound preferably combined with an effective amount of an insoluble cation exchange material and an effective amount of anhydrous Magnetite mixed uniformly together. Povidone iodine may be added for enhanced antimicrobial properties. In the method, a quantity of the composition is magnetically attached to a surface of a magnet, after which the powderous mixture is applied to the wound by pressing the surface covered with the powderous compound against the wound for a time sufficient to clot the blood to arrest substantial further blood flow from the wound.

Подробнее
27-06-2013 дата публикации

Antimicrobial disposable absorbent articles

Номер: US20130165880A1
Принадлежит: 3M Innovative Properties Co

Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.

Подробнее
01-08-2013 дата публикации

Temporary Embolization Using Inverse Thermosensitive Polymers

Номер: US20130195753A1
Принадлежит: Genzyme Corp

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound.

Подробнее
01-08-2013 дата публикации

Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith

Номер: US20130195928A1
Принадлежит: Pioneer Surgical Technology Inc

The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.

Подробнее
08-08-2013 дата публикации

Dermal filler compositions for fine line treatment

Номер: US20130203696A1
Принадлежит: Allergan Inc

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.

Подробнее
08-08-2013 дата публикации

Filler composition for tissue reinforcement

Номер: US20130203856A1

The present invention relates to a filler composition for tissue reinforcement, including hyaluronic acid and alkylene diamine crosslinked hydrogel. The filler composition exhibits the positive physical properties required for tissue reinforcement, such as biocompatibility and swelling ability, as well as useful effects in that the same can remain in vivo for a long time.

Подробнее
19-09-2013 дата публикации

Injectable chitosan mixtures forming hydrogels

Номер: US20130244972A1
Принадлежит: MOR RESEARCH APPLICATIONS LTD

A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

Подробнее
03-10-2013 дата публикации

Medical absorbable hemostatic material for bone wounds and preparation method therefor

Номер: US20130261192A1

A medical absorbable hemostatic and wound healing promoting material for bone wounds and a preparation method thereof. The absorbable hemostatic material for bone wounds is formed of 40-95% of a base material and 5-60% of an adjuvant, based on weight percent, wherein the base material is an oligosaccharide, a polysaccharide, or a mixture of the oligosaccharide and the polysaccharide, and the adjuvant includes (1) one or more polyhydric alcohols, (2) one or more vegetable oils, and (3) one or more emulsifying agents. The method for preparing the absorbable hemostatic and wound healing promoting material for bone wounds comprises mixing a base material and an adjuvant at prescribed amounts by chemical blending or latex blending, cooling to form a solid lump, packaging, and sterilizing.

Подробнее
17-10-2013 дата публикации

Injectable Cross-Linked Polymeric Preparations and Uses Thereof

Номер: US20130272969A1

A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

Подробнее
24-10-2013 дата публикации

Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens

Номер: US20130280410A1
Принадлежит: COVIDIEN LP

A method and device for local delivery of a water-insoluble therapeutic agent to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which comprises poly(HEMA) complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.

Подробнее
05-12-2013 дата публикации

Injectable microspheres for dermal augmentation and tissue bulking

Номер: US20130323316A1
Принадлежит: Biosphere Medical Inc

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Подробнее
26-12-2013 дата публикации

Cross-linked polymers and implants derived from electrophilically activated polyoxazoline

Номер: US20130345334A1
Принадлежит: Bender Analytical Holding BV

One aspect of the invention relates to a biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent, said electrophilically activated POX comprising m electrophilic groups; and said nucleophilic cross-linking agent comprising n nucleophilic groups, wherein the m electrophilic groups are capable of reaction with the n nucleophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m≧3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. The invention further relates to biocompatible medical products comprising such a cross-linked POX-polymer. Also provided is a kit for producing a biocompatible, cross-linked POX-polymer. The invention further provides a tissue adhesive medical product comprising at least 1% by weight of dry matter of EL-POX, said EL-POX comprising at least 2 electrophilic groups, including at least one pendant electrophilic group. The polymers according to the invention have excellent implant and/or sealing characteristics.

Подробнее
30-01-2014 дата публикации

Bone graft materials and methods

Номер: US20140031950A1
Принадлежит: Biostructures LLC

Compositions, materials, methods and kits for bone grafting are described. In some embodiments, a bone graft composition includes about 15% to about 20% by weight collagen, about 55% to about 70% by weight bioactive glass, and about 15% to about 30% by weight a calcium phosphate. The bioactive glass and the calcium phosphate together are about 80% to about 85% by weight of the bone graft composition. In some embodiments, a bone graft composition includes a collagen matrix and a plurality of bioactive glass particulates dispersed throughout the collagen matrix. The collagen matrix is about 20% to about 60% by weight of the bone graft composition, and the bioactive glass is about 40% to about 80% of the bone graft composition. In some embodiments, a majority of the bioactive glass particulates are about 53 μm to about 425 μm in size.

Подробнее
06-02-2014 дата публикации

Hyaluronic acid composition

Номер: US20140039061A1
Принадлежит: Individual

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and a method of manufacturing such a composition.

Подробнее
20-02-2014 дата публикации

Placental tissue grafts modified with a cross-linking agent and methods of making and using the same

Номер: US20140052247A1
Принадлежит: Mimedx Group Inc

Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of chorion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

Подробнее
06-03-2014 дата публикации

Enhanced low friction coating for medical leads and methods of making

Номер: US20140067028A1
Принадлежит: Cardiac Pacemakers Inc

An implantable or insertable medical device can include a silicone substrate and a plasma-enhanced chemical vapor deposition coating on the silicone substrate. The coating may include a silicon-containing compound. A method of forming the coating is also provided.

Подробнее
13-03-2014 дата публикации

Collagen scaffolds, medical implants with same and methods of use

Номер: US20140073704A1
Принадлежит: UNIVERSITY OF SOUTH FLORIDA

The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.

Подробнее
13-03-2014 дата публикации

Composition, system and method for tissue augmentation

Номер: US20140074012A1
Автор: Ernesto ANDRADE
Принадлежит: Individual

A composition for purposes of augmentation contains a plurality of substantially spherical, biocompatible semi-solid beads each having a diameter in the range of about 1 millimeter to 10 millimeters. The composition also includes a delivery solvent for sanitary lubrication of the beads. An inventive system and method are utilized to systematically administer the composition into a patient's adipose tissue for customized augmentation. The system can comprise one or more dispensing apparatus, such as in the form of one or more pre-filled syringes. The size and number of pre-filled dispensing apparatus can be selected and organized into one or more kits for use in connection with a specific treatment or group of treatments. The inventive method involves selecting an insertion site in proximity to an identified target tissue, inserting the dispensing apparatus into the tissue through the insertion site, and infiltrating the composition into the tissue in a controlled manner.

Подробнее
27-03-2014 дата публикации

Method and System for Treatment of Biological Tissue

Номер: US20140087000A1
Автор: Robert G. Matheny
Принадлежит: Individual

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.

Подробнее
06-01-2022 дата публикации

Hyaluronic acid composition

Номер: US20220000752A1
Принадлежит: Galderma Holding SA

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

Подробнее
07-01-2021 дата публикации

Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation

Номер: US20210000736A1
Принадлежит: STEMFORM APS

The present invention relates to a composition comprising ex-vivo expanded adipose tissue derived stem cell (ASC) or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5,0×10−2,0×10ASCs/mL fat; for example 1,0×10−2,0×10and the use of ex-vivo expanded adipose tissue-derived stem cells or ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as an agent for cosmetic breast filling/augmentation or for facial filling/rejuvenation. 1. A composition comprising ex-vivo expanded adipose tissue-derived stem cell (ASC) enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5 ,0×10−2 ,0×10ASCs/mL fat.2. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as a breast filling agent.3. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells as a facial filling agent.4. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling.5. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells for cosmetic facial filling.6. Cosmetic method of breast filling wherein adipose tissue-derived stem cell (ASC) enriched fat grafts is mixed with harvested fat tissue at a ratio of 5 ,0×10−2 ,0×10ASCs/mL fat , and wherein the fat is injected as aliquots or as strings with a long needle horizontally (parallel to the body) by inserting the needle from several points around the areola margin and at several points at the inframammary fold in variable directions and planes to achieve an even and natural appearing distribution of the graft.7. Cosmetic method of facial filling wherein expanded adipose tissue-derived stem cell (ASC) enriched fat grafts or ex-vivo expanded adipose tissue-derived stem ...

Подробнее
03-01-2019 дата публикации

HYALURONIC ACID COMPOSITION

Номер: US20190000740A1
Принадлежит: Q-Med AB

An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition. 1a hyaluronic acid,a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof, andan ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat.. An injectable hyaluronic acid composition comprising The present application is a continuation of U.S. application Ser. No. 13/983,448, filed on Oct. 2, 2013, which is a continuation of U.S. national stage of International Application No. PCT/EP2012/051875, filed on Feb. 3, 2012, which claims the benefit of European Application No. 11153232.1, Feb. 3, 2011. The entire contents of each of U.S. application Ser. No. 13/983,448, International Application No. PCT/EP2012/051875, and European Application No. 11153232.1 are hereby incorporated herein by reference in their entirety.The present invention relates to the field of injectable hyaluronic acid compositions and the use of such compositions in cosmetic and or medical applications.One of the most widely used biocompatible polymers for medical use is hyaluronic acid. It is a naturally occurring polysaccharide belonging to the group of glycosaminoglycans (GAGs). Hyaluronic acid and the other GAGs are negatively charged heteropolysaccharide chains which have a capacity to absorb large amounts of water. Hyaluronic acid and products derived from hyaluronic acid ...

Подробнее
04-01-2018 дата публикации

Compositions, methods and devices for forming implants from injected liquids

Номер: US20180000756A1
Принадлежит: PATHAK HOLDINGS LLC

A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm 2 . The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent.

Подробнее
03-01-2019 дата публикации

Method of treatment of osteochondral defects

Номер: US20190000886A1
Автор: Duncan Ross
Принадлежит: Individual

Method and pharmaceutical compositions for enhancing osteochondral tissue, so that osteochondral defects may be repaired by the body and/or prevented or lessened. The methods primarily include administering into a joint cavity, in doses not more frequently than daily for up to 13 days, an effective amount of anti-inflammatory cell growth pharmaceutical composition including cell secretory microvesicles derived from placental cotyledon derived mesenchymal stem cells that secrete growth factors; and administering into the joint cavity on day 14 (and as appropriate thereafter) an effective amount of pharmaceutical composition for cell differentiation and growth including chondrocyte derived exosomes.

Подробнее
07-01-2021 дата публикации

BONE FRACTURE REPAIR BY TARGETING OF AGENTS THAT PROMOTE BONE HEALING

Номер: US20210000962A1
Принадлежит:

Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein. 159-. (canceled)60. A method of treating a bone fracture , comprising the step of: administering to a patient suffering from the bone fracture a therapeutic amount of a compound of the formula ,{'br': None, 'sub': 'n', 'A-B-(MA)-C-D,'} A is at least one negatively charged oligopeptide;', 'B is a spacer;', 'C is a linker, wherein the linker includes at least one oligopeptide that is a substrate for the protease cathepsin K;', 'D is an active compound that promotes the healing of bone fractures comprising at least one compound selected from the group consisting of: prostaglandin E1 and prostaglandin E2;', 'MA is a backbone structure which is linked to both B and C; and', 'n is 1 to 20, or 1-100, or 1-200, or 1-500 or 1-1,000, or any digit greater than or equal to 1 and less than or equal to 1,000., 'wherein61. The method of claim 60 , further comprising the step of: identifying a patient having a bone fracture.62. The method of claim 60 , wherein A is an acidic oligopeptide.63. The method of claim 62 , wherein the acidic oligopeptide comprises not less than 4 and not more than 10 amino acids claim 62 , not less than 4 and not more than 15 amino acids claim 62 , or not less than 4 and not more than 10 amino acids.64. The method of claim 62 , wherein the acidic ...

Подробнее
02-01-2020 дата публикации

Injectable Self-assembling Antibacterial Peptide Hydrogels

Номер: US20200000875A1
Принадлежит: NEW JERSEY INSTITUTE OF TECHNOLOGY

A set of cationic amphiphilic self-assembled peptides (CASPs) is presented that employ high-charge density at fiber edges to disrupt bacterial membranes. CASP nanofibers are effective against biofilms. There is an inherent trade-off between the ability of the peptides to undergo nanofibrous self-assembly and having a high terminal charge density required for effective bactericidal efficacy. The self-assembled peptide hydrogel presented achieves a balance of these opposing factors. Also demonstrated is the applicability of the new composition in an injectable hydrogel formulation. A CASP platform may be useful for topical application and integration into medical coatings, grafts, devices, and prostheses, thereby reducing risk of bacterial infection and related failure. 2. The anti-bacterial hydrogel of claim 1 , wherein the CASP intrinsically undergoes self-hydrogelation in aqueous solutions without addition of an exogenous gel base.3. The anti-bacterial hydrogel of claim 2 , wherein the hydrogel is topically applied or integrated into a wound bed directly claim 2 , or integrated into medical coatings claim 2 , grafts claim 2 , devices claim 2 , and prostheses for reducing risk of bacterial infection and related failure.4. The anti-bacterial hydrogel of claim 1 , wherein the lysine (K) may be substituted for a positively charged amino acid selected from a group consisting of arginine (Arg claim 1 , R) claim 1 , histidine (His claim 1 , H) claim 1 , modified or unnatural positively charged monovalent or polyvalent amino acids claim 1 , and any combination thereof.5. The anti-bacterial hydrogel of claim 1 , wherein the peptide CASP-K6 contains a varied combination of K claim 1 , S claim 1 , and L.6. The anti-bacterial hydrogel of claim 1 , wherein the peptide CASP-6 improves antimicrobial effects by either increasing or decreasing the number of K claim 1 , S claim 1 , and L amino acids.7. The anti-bacterial hydrogel of claim 1 , wherein the peptide CASP-6 inhibits ...

Подробнее
07-01-2016 дата публикации

Hemostatic Compositions

Номер: US20160000962A1
Принадлежит: FUJIFILM MANUFACTURING EUROPE B.V.

A cross linked recombinant gelatin composition for the induction of blood coagulation and hemostasis. 115.-. (canceled)16. A method for hemostatic treatment , comprising administering , to a patient with bleeding , a composition comprising a cross-linked gelatin with an isoelectric point of at least 7 , wherein the gelatin is a recombinant gelatin which is cross-linked using a carbodiimide and which comprises at least one RGD motif.17. The method according to wherein the gelatin prior to cross-linking has an isoelectric point of at least 7.18. The method according to wherein the gelatin prior to cross-linking has an isoelectric point of at least 9.19. The method according to wherein after cross-linking the cross-linked gelatin has an isoelectric point of at least 9.20. The method according to wherein the recombinant gelatin is free of hydroxyproline and hydroxylysine residues.21. The method according to wherein the recombinant gelatin comprises at least 0.40 mmol/g lysine residues before cross-linking.22. The method according to wherein the recombinant gelatin comprises a ratio between the total arginine and lysine amino acid residues and the total glutamine and asparagine amino acid residues that is at least 1.0.23. The method according to wherein the recombinant gelatin has a molecular weight of at least 50 kDa.24. The method according to wherein the gelatin is cross-linked using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC).25. The method according to wherein the recombinant gelatin is represented by CBE3. The present invention is directed to cross-linked gelatin compositions for medical use as a hemostatic agent. The present invention is further directed to the preparation of such compositions. These compositions are useful as hemostatic agents in a variety of medical applications, including vascular plug type devices, wound closure devices, dressings for use to treat incisions, seeping wounds, and the like.Hemostatic agents have a wide range ...

Подробнее
07-01-2016 дата публикации

MATERIALS FOR GASTROINTESTINAL OBSTRUCTION PREVENTION

Номер: US20160000966A1
Принадлежит:

Materials and methods for preventing gastrointestinal obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. The peptide may undergo self-organization under physiological conditions and/or in the presence of a cation. 1. A method of preventing gastrointestinal obstruction in a subject comprising:introducing a catheter into a gastrointestinal tract;positioning an end of the catheter in a target area of the gastrointestinal tract in which at a prevention of gastrointestinal obstruction is desired;administering through the catheter a solution comprising a self-assembling peptide comprising between about 7 amino acids and 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions of the gastrointestinal tract to provide prevention of gastrointestinal obstruction; andremoving the catheter from the gastrointestinal tract.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the gastrointestinal tract.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the gastrointestinal tract;introducing the catheter;positioning the end of the catheter in the target area;administering the solution;removing the catheter; andmonitoring the gastrointestinal tract after removing the catheter.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the gastrointestinal tract.5. The method of claim 3 , further comprising visualizing the region in a time period about one week subsequent the administration.6. The method of claim 5 , further comprising visualizing the region in a time period about four weeks subsequent the administration.7. The method of claim 6 , further comprising visualizing the region in a time period about eight weeks subsequent the ...

Подробнее
07-01-2021 дата публикации

Composition for hemostasis and container comprising same

Номер: US20210001002A1
Принадлежит:

The present invention relates to a composition for hemostasis which contains collagen, stabilizer, and thrombin, and a container including the same. The present invention is applicable to a bleeding patient requiring emergency treatment with a simple method of use. There is no toxicity and no problem of blood infection. A biodegradation rate is fast. In this regard, the present invention achieves an excellent hemostatic effect. Therefore, the composition for hemostasis is useful as a hemostat. 1. A composition for hemostasis comprising collagen;stabilizer; andthrombin,wherein the stabilizer is disposed between the collagen and the thrombin so that the collagen and the thrombin are separated from each other.2. The composition of claim 1 , wherein the collagen is crosslinked collagen.3. The composition of claim 2 , wherein the crosslinked collagen is prepared using a preparing method including(S1) a step of treating the collagen with ethanol or methanol,(S2) a step of preparing collagen solution having pH 2 to pH 4 by adding acid to the collagen treated in the step (S1),(S3) a step of preparing esterified collagen by performing centrifugation on the collagen solution prepared in the step (S2) after bringing the collagen solution into a neutral state,(S4) a step of preparing the crosslinked collagen by adding a crosslinking agent to esterified collagen prepared in the step of (S3), and(S5) a step of performing freeze drying on the crosslinked collagen prepared in the step (S4) after the crosslinked collagen is dispersed into purified water.4. The composition of claim 2 , wherein a molecular weight of the crosslinked collagen is 100 claim 2 ,000 to 1 claim 2 ,000 claim 2 ,000 Dalton.5. The composition of claim 1 , wherein the collagen is included as much as 40 to 97 weight % in a gross weight of the composition for hemostasis.6. The composition of claim 1 , wherein the stabilizer is at least one selected from a group consisting of albumin (human serum albumin) claim 1 , ...

Подробнее
07-01-2021 дата публикации

WOUND-TREATING ABSORBENT

Номер: US20210001003A1
Принадлежит:

The present disclosure provides wound-treating absorbent kits that comprise a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran. In some embodiments, the first hemostatic composition has a first degree of crosslinking, and the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking. Also provided are methods of treating a wound by selecting a hemostatic composition from the disclosed set of hemostatic compositions, and administering the selected hemostatic composition to a site of the wound. 1. A wound-treating absorbent kit comprising:a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, wherein the first hemostatic composition has a first degree of crosslinking, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, wherein the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking.2. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions includes crosslinked β-cyclodextrin.3. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions is in powdered form.4. The wound-treating absorbent kit of comprising a pharmaceutically acceptable diluent for reconstitution of any of the first and second hemostatic compositions.5. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions comprises a ...

Подробнее
07-01-2016 дата публикации

COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN

Номер: US20160000972A1
Принадлежит:

The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention. 1. A method of preventing or inhibiting vertebral compression fractures comprising:providing a composition comprising a PDGF solution disposed in a biocompatible matrix; and,applying the composition to at least one vertebral body.2. The method of claim 1 , wherein applying comprises injecting the at least one vertebral body with the composition.3. The method of claim 1 , wherein the at least one vertebral body comprises a high risk vertebral body.4. A method for promoting or accelerating bone formation in a vertebral body comprising:providing a composition comprising a PDGF solution disposed in a biocompatible matrix; and,applying the composition to at least one vertebral body.5. The method of claim 4 , further comprising providing at least one pharmaceutical composition; and claim 4 ,administering the pharmaceutical composition locally to a patient.6. The method of claim 5 , wherein administering the pharmaceutical composition locally comprises disposing the pharmaceutical composition in or around the at least one vertebral body.7. The method of claim 4 , further comprising providing at least one pharmaceutical composition; and claim 4 ,administering the pharmaceutical composition systemically to a patient.8. The method of claim 7 , wherein administering the pharmaceutical composition systemically comprises oral administration claim 7 , intravenous administration ...

Подробнее
07-01-2021 дата публикации

BIOGUM AND BOTANICAL GUM HYDROGEL BIOINKS FOR THE PHYSIOLOGICAL 3D BIOPRINTING OF TISSUE CONSTRUCTS FOR IN VITRO CULTURE AND TRANSPLANTATION

Номер: US20210001009A1
Принадлежит:

Bioink compositions comprising a biomaterial (mammalian, plant based, synthetically derived, or microbially derived) such as a hydrogel and a microbial-, fungal-, or plant-produced polysaccharide, with or without cells, for use in the 3D bioprinting of human tissues and scaffolds are described. The bioink compositions have excellent printability and improved cell function, viability and engraftment. Furthermore, the bioink compositions can be supplemented through the additional of auxiliary proteins and other molecules such as growth factors including extracellular matrix components, Laminins, super affinity growth factors and morphogens. The bioink compositions can be used under physiological conditions related to 3D bioprinting parameters which are cytocompatible (e.g. temperature, printing pressure, nozzle size, bioink gelation process). The combination of a biogum-based biomaterial together with mammalian, plant, microbial or synthetically derived hydrogels exhibited improvement in printability, cell function and viability compared to tissues printed with bioink not containing biogums. 111-. (canceled)12. A method for diagnosing a disease of a human individual comprising the steps of:a. providing a sample from an individual of a bioprinted tissue or scaffold prepared by a method for 3D bioprinting of human or mammalian tissue comprising:bioprinting a composition comprising one or more microbial, fungal, or plant based or produced biogum and one or more biomaterials derived from mammalian, plant, microbial or synthetically derived hydrogels in a manner that combines the one or more biogum and the one or more biomaterials with human or mammalian cells or in a manner that forms at least one scaffold;b. determining the presence and amount of one or more scaffold or tissue proteins in the sample, wherein the presence and amount of the one or more scaffold or tissue proteins in the sample is indicative of the presence of diseases in the tissue or organ of the ...

Подробнее
07-01-2021 дата публикации

Uniaxially-aligned nanofiber scaffolds and methods for producing and using same

Номер: US20210001010A1
Принадлежит: Childrens Healthcare of Atlanta Inc

Oral cavity wound healing occurs in an environment that sustains ongoing physical trauma and is rich in bacteria. Patients undergoing cleft palate repair have a high degree of wound healing complications, such as oronasal fistula (ONF) formation. Following hard palate injury, ONF was created that demonstrated little change in pro-regenerative monocytes LY6Clo monocytes; however, there were increased M2 macrophages observed. Delivery of FTY720 nanofiber scaffolds following hard palate injury prevented ONF formation, allowed complete wound healing and was associated with increased LY6Clo monocytes and pro-regenerative M2 macrophages. Evaluation of interleukin gene expression revealed reduction in pro-inflammatory IL1 and IL6 and increased expression of pro-regenerative IL10 with FTY720 nanofiber delivery. The ability of FTY720 scaffolds to increase LY6Clo monocytes, increase M2 macrophages and alter the interleukin expression during hard palate mucosal healing demonstrates the ability of a FTY720-based autotherapy to improve oral cavity wound healing.

Подробнее
04-01-2018 дата публикации

Composition and methods for treating ischemic wounds and inflammatory conditions

Номер: US20180000905A1
Принадлежит: Southwest Technologies Inc

Methods, compositions, and treatment protocols for treating ischemic wounds and inflammatory conditions in a patient. The treatment protocols comprise or consist of using a modified collagen gel (MCG) to promote healing of ischemic wounds and reduce inflammation at the wound site and in other inflammatory conditions. The modified collagen gel comprises generally a dispersion of collagens in an aqueous matrix comprising water and glycerine, where the amount of Type I collagen is greater than the amount of Type II and Type III collagens in the gel.

Подробнее
04-01-2018 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20180000982A1
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

Подробнее
04-01-2018 дата публикации

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

Номер: US20180000983A1
Принадлежит:

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

Подробнее
04-01-2018 дата публикации

DENSE HYDROGELS

Номер: US20180000989A1
Принадлежит:

There is provided a method for preparing a dense hydrogel comprising an at least partially gelled hydrogel, placing the at least partially gelled hydrogel in fluid communication with an end of a capillary, and driving the at least partially gelled hydrogel into the capillary to form a dense hydrogel. There is also provided a system for preparing the dense hydrogel comprising a capillary having a bore; and a driver in communication with an end of the capillary for driving an at least partially gelled hydrogel into the bore of the capillary to form a dense hydrogel. 196-. (canceled)97. A system for preparing a dense hydrogel , the system comprising:a capillary having a first open end, a second open end and a bore defined therebetween;a driver in communication with the second open end of the capillary, the driver arranged to selectively exert:a negative pressure to drive a hydrogel into the capillary to form a dense hydrogel in the capillary, anda positive pressure to drive the dense hydrogel out of the capillary.98. The system of claim 97 , wherein the driver is a manual or an automatic pump.99. The system of claim 97 , further comprising the hydrogel claim 97 , the hydrogel being a biocompatible material.100. The system of claim 99 , wherein the hydrogel is selected from collagen claim 99 , hyaluronan claim 99 , chitosan claim 99 , fibrin claim 99 , gelatin claim 99 , alginate claim 99 , agarose claim 99 , polyacrylamide claim 99 , poly(ethylene glycol) claim 99 , poly(vinyl alcohol) claim 99 , polyacrylic acid claim 99 , hydroxyl ethyl methacrylate claim 99 , polyanhydrides claim 99 , poly(propylene fumarate) claim 99 , and mixtures of the same.101. The system of claim 99 , wherein the hydrogel is collagen type I.102. The system of claim 99 , wherein the first open end of the capillary can be brought into contact with the hydrogel.103. The system of claim 99 , wherein the hydrogel includes at least one bioactive agent.104. The system of claim 102 , wherein the at ...

Подробнее
04-01-2018 дата публикации

HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE

Номер: US20180000992A1
Автор: Lebreton Pierre F.
Принадлежит:

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. 1. A device for restoring fat loss-related tissue volume loss in the face , the device comprising:a syringe;a sterile viscoelastic gel contained in the syringe, the gel comprising hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and including an amount of lidocaine.2. The device of wherein the syringe has an internal volume of about 0.4 mL to about 3 mL.3. The device of wherein the syringe has an internal volume between about 0.5 mL and about 1.5 mL.4. The device of wherein the syringe has an internal volume between about 0.8 mL and about 2.5 mL.5. The device of wherein the amount of lidocaine present in the gel is 0.3%.6. A device for restoring fat loss-related tissue volume loss in the face claim 2 , the device comprising:a syringe having an internal volume between about 0.8 mL and about 2.5 mL;a sterile viscoelastic gel contained in the syringe, the gel comprising hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and including 0.3% lidocaine. This application is a continuation of U.S. patent application Ser. No. 14/754,504, filed on Jun. 29, 2015, which is a continuation of U.S. patent application Ser. No. 14/242,752, filed on Apr. 1, 2014, which is a continuation of U.S. patent application Ser. No. 13/419,079, filed Mar. 13, 2012, now ...

Подробнее
02-01-2020 дата публикации

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

Номер: US20200000926A1
Принадлежит: COSMO TECHNOLOGIES LTD.

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A kit comprising a pharmaceutical composition in a container , wherein the pharmaceutical composition comprises:(a) at least one poloxamer selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, or a mixture thereof; and(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C. in vitro.2. The kit according to claim 1 , wherein the container is selected from an ampoule claim 1 , a vial claim 1 , a bottle claim 1 , and a pre-filled syringe.3. The kit according to claim 2 , wherein the container is an ampoule.4. The kit according to claim 3 , wherein the ampoule contains from 10 mL to 50 mL of the pharmaceutical composition.5. The kit according to claim 2 , wherein the container is a vial.6. The kit according to claim 5 , wherein the vial contains from 10 mL to 50 mL of the pharmaceutical composition.7. The kit according to claim 2 , wherein the container is a bottle.8. The kit according to claim 2 , wherein the container is a pre-filled syringe.9. The kit according to claim 8 , wherein the pre-filled syringe contains from 5 mL to 10 mL of the pharmaceutical composition.10. A method for creating a cushion in a submucosal tissue in the gastrointestinal tract of a patient claim 8 , comprising injecting into the submucosal tissue a pharmaceutical composition comprising:(a) at least one poloxamer selected from poloxamer 124, ...

Подробнее
02-01-2020 дата публикации

Solid dressing for treating wounded tissue and processes for mixing fibrinogen and thrombin while preserving fibrin-forming ability, compositions produced by these processes, and the use thereof

Номер: US20200000957A1
Принадлежит: Resource Transition Consultants LLC

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

Подробнее
02-01-2020 дата публикации

CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION

Номер: US20200000968A1
Принадлежит:

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component. 1. A method of improving fat graft volume retention , the method comprising: water;', 'a crosslinked macromolecular matrix comprising hyaluronic acid crosslinked to collagen via a plurality of crosslink units, wherein at least a portion of the crosslink units comprise an amide bond, an ester bond or both; and the crosslinked macromolecular matrix has a weight ratio of the hyaluronic acid to the collagen of 1:1 to 7:1;', 'wherein said hydrogel component has a hyaluronic acid concentration of 6 mg/mL to 21 mg/mL and a collagen concentration of 3 mg/mL to 12 mg/mL; and, 'providing a hydrogel component, the hydrogel component comprisingblending the hydrogel component with a lipoaspirate to form a lipoaspirate/hydrogel graft, wherein the lipoaspirate/hydrogel graft has a lipoaspirate:hydrogel component volume ratio of 1:1 to 5:1; andadministering the lipoaspirate/hydrogel graft into a soft tissue in an area on a body of an individual, wherein the lipoaspirate/hydrogel graft promotes fat graft survival in the soft tissue area on the body.2. The method of claim 1 , wherein the soft tissue comprises a volume claim 1 , and the administering of the lipoaspirate/hydrogel graft increases the soft tissue volume of the area on the body.3. The method of claim 2 , wherein the administering of the lipoaspirate/hydrogel graft increases fat volume in the area on the body.4. The method of claim 3 , wherein retention of the fat volume is increased as compared to administering the lipoaspirate alone.5. The method of claim 1 , wherein the method reduces variability in retained fat graft volume retention obtained from the administered lipoaspirate/hydrogel graft in the ...

Подробнее
02-01-2020 дата публикации

HYALURONIC ACID COMPOSITIONS INCLUDING MEPIVACAINE

Номер: US20200000969A1
Принадлежит: LABORATOIRES VIVACY

A sterilized aqueous composition includes at least one hyaluronic acid or salt thereof and at least mepivacaine or salt thereof. The weight ratio between the concentration of hyaluronic acid [HA] and the concentration of mepivacaine [MEPI]-[HA]/[MEPI]- is no lower than 0.1. Mepivacaine may be used as a substitute for lidocaine in an equivalent amount in order to obtain a hyaluronic acid composition including a local anaesthetic with rheological properties after heat sterilization that are superior to the rheological properties of the same composition of hyaluronic acid except including lidocaine. 1. A sterilized aqueous composition , comprising:at least one hyaluronic acid or a salt thereof;mepivacaine or pharmaceutically acceptable salt thereof; andat least one antioxidant that is a polyol, wherein:the concentration of hyaluronic acid or salt thereof [HA] is between 2 mg/g and 50 mg/g of total weight of said composition;the mass ratio between the concentration of hyaluronic acid or salt thereof [HA] and the concentration of mepivacaine or salt thereof [MEPI]:[HA]/[MEPI] is greater than or equal to 0.1 ([HA]/[MEPI]≥0.1); andthe polyol content is between 20 mg/g and 40 mg/g of total weight of said composition.2. The sterilized aqueous composition as claimed in claim 1 , wherein [HA]/[MEPI] is between 0.1 and 50 (0.1≤[HA]/[MEPI]≤50).3. The sterilized aqueous composition as claimed in claim 1 , wherein the concentration of mepivacaine or salt thereof [MEPI] is between 0.01 mg/g and 50 mg/g of total weight of said composition.4. The sterilized aqueous composition as claimed in claim 1 , wherein mepivacaine or salt thereof is selected from the group consisting of racemic mepivacaine hydrochloride claim 1 , (R)-mepivacaine hydrochloride claim 1 , (S)-mepivacaine hydrochloride claim 1 , racemic mepivacaine claim 1 , (R)-mepivacaine claim 1 , (S)-mepivacaine claim 1 , and pharmaceutically acceptable salts thereof.5. The sterilized aqueous composition as claimed in claim 1 , ...

Подробнее
05-01-2017 дата публикации

METHODS AND DRESSINGS FOR SEALING INTERNAL INJURIES

Номер: US20170000922A1
Принадлежит: STB, Ltd.

Disclosed are solid and frozen haemostatic materials and dressing's consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings. 1. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material has a plurality of particles , wherein said particles each have the same composition , and wherein the moisture content of said hemostatic material is from 6% to 44%.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material has a plurality of particles , wherein said particles each have the same composition , and wherein the moisture content of said hemostatic material is from 1% to 6%.3. A method for treating wounded internal tissue in a mammal comprising applying to svounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material is cast or formed as a single piece.4. The method of claim 1 , wherein said haemostatic material includes at least one support layer.5. The method of claim 4 , wherein said support layer comprises a backing material.6. The method of claim 4 ...

Подробнее
05-01-2017 дата публикации

PLASTICIZERS FOR A BIODEGRADABLE SCAFFOLDING AND METHODS OF FORMING SAME

Номер: US20170000930A1
Принадлежит:

Methods of making polymeric devices, such as stents, with one or more modifications such as addition of plasticizers, to improve processing, and the devices made by these methods. 1. A method of fabricating a medical device , the method comprising:processing a polymer to form a medical device or a polymer construct, the processing occurring at a high temperature, the high temperature being above the melting temperature of the polymer, if the polymer exhibits a melting temperature above 35° C., or if the polymer does not exhibit a melting temperature above 35° C., at a temperature 100° C. higher than the glass transition temperature (Tg) of the polymer, or 75° C., if 75° C. is greater than 100° C. above the Tg of the polymer; 'wherein the plasticizer is different from any solvent used in production of the polymer;', 'adding a plasticizer to the polymer prior to, during, or both prior to and during the processing of the polymer;'}removing at least 75 weight % of the plasticizer from the processed polymer, the removal comprising heating the processed polymer to and maintaining the processed polymer at a temperature above the glass transition temperature of the polymer or above 28° C., if the glass transition temperature of the polymer is lower than 25° C., and below the melting temperature of the polymer, if the polymer has a melting temperature above 28° C., or if the polymer does not have a melting temperature above 28° C., below the temperature that is 75° C. greater than the glass transition temperature of the polymer, or below 60° C., if 60° C. is higher than 75° C. greater than the glass transition temperature of the polymer;optionally executing one or more additional operations on the medical device or on the polymer construct;wherein the polymer has a number average molecular weight as measured by GPC using polystyrene standards of at least 250,000 g/mole, but not more than 3,000,000 g/mole, the polymer has a weight average molecular weight of at least 300,000 ...

Подробнее
03-01-2019 дата публикации

Method Of Preparing Calcification-Resistant Bioprosthetic Tissue

Номер: US20190001023A1

Methods of preparing calcification-resistant bioprosthetic tissue include providing fresh biological tissue, cross-linking the tissue, treating the cross-linked tissue with an alcohol for a time sufficient to allow the alcohol to be diffused into the tissue, and treating the alcohol-treated fixed tissue with a polyol for a time sufficient to allow fluid in the tissue to be replaced by the polyol. The methods may include sterilizing the cross-linked tissue in a solution including propylene oxide or peracetic acid either before or after the alcohol treatment step; or drying the alcohol/polyol-treated, cross-linked tissue, sterilizing the dried tissue by exposure to ethylene oxide or peracetic acid, and storing the sterilized tissue in a dry, ambient environment. The treated tissue may be a tissue component for a bioprosthetic valve, a valve assembly for a bioprosthetic valve or a fully assembled bioprosthetic valve incorporating the tissue. 1. A method of preparing calcification-resistant tissue , comprising:providing fresh biological tissue;cross-linking the tissue to produce fixed tissue;treating the fixed tissue with an alcohol for a time sufficient to allow the alcohol to be diffused into the tissue to produce alcohol-treated fixed tissue; andtreating the alcohol-treated fixed tissue with a polyol for a time sufficient to allow fluid in the tissue to be replaced by the polyol to produce alcohol/polyol-treated fixed tissue.2. The method of claim 1 , further comprising sterilizing the fixed tissue in a solution comprising propylene oxide or peracetic acid prior to the step of treating the fixed tissue with the alcohol.3. The method of claim 1 , further comprising sterilizing the alcohol/polyol-treated fixed tissue in a solution comprising propylene oxide or peracetic acid.4. The method of claim 1 , further comprising:drying the alcohol/polyol-treated fixed tissue to produce dried tissue; andstoring the dried tissue in a dry, ambient environment.5. The method of ...

Подробнее
03-01-2019 дата публикации

TECHNIQUES FOR TREATMENT OF ABSCESSES

Номер: US20190001028A1

This document provides devices, system, and methods for treating an abscess cavity. For example, procedures that involve supplementing a biocompatible filler material with a therapeutic agent to promote tissue regeneration and healing are provided. The biocompatible filler materials that are treated with a therapeutic agent are implanted into the abscess cavity. The biocompatible filler material provides a tissue growth scaffold, and the therapeutic agent enhances tissue growth and healing. 1. A method for treating a fistula of a mammal , said method comprising:(a) obtaining a synthetic, bioabsorbable, non-woven material that is configured for implantation into the fistula,(b) soaking the material in a solution comprising adipose-derived stem cells and platelet derivative material for from about 1 hour to about 5 days, wherein the adipose-derived stem cells and platelet derivative material impregnate the material, thereby forming a treated material, and(c) implanting the treated material into the fistula.2. The method of claim 1 , wherein said mammal is a human.35-. (canceled)6. The method of claim 1 , wherein said fistula is an anal fistula.78-. (canceled)9. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 18 hours to about 5 days.10. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 1 day to about 5 days.11. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 3 days to about 5 days. This application is a divisional of U.S. Ser. No. 14/435,778, filed Apr. 15, 2015, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2013/065631, having and International Filing Date of Oct. 18, 2013, which a claims the benefit of U.S. Provisional Application Ser. No. 61/715,506, filed Oct. 18, 2012. The disclosures of the prior applications are ...

Подробнее
05-01-2017 дата публикации

NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES

Номер: US20170002041A1

The present invention relates to hydrophobic peptides and/or peptidomimetics capable of forming a (nanofibrous) hydrogel and hydrogels comprising said hydrophobic peptides and/or peptidomimetics and to various uses, such as in regenerative medicine, injectable therapies, delivery of bioactive moieties, wound healing, 2D and 3D synthetic cell culture substrate, biosensor development, biofunctionalized surfaces, and biofabrication. 1. A hydrophobic peptide and/or peptidomimetic capable of forming a hydrogel , the hydrophobic peptide and/or peptidomimetic having the general formula:{'br': None, 'sub': a', 'b, 'Z—(X)—Z′'}whereinZ is an N-terminal protecting group;X is, at each occurrence, independently selected from the group consisting of aliphatic D- or L-amino acids and aliphatic D- or L-amino acid derivatives, and wherein the overall hydrophobicity decreases from N- to C-terminus;a is an integer selected from 2 to 7, preferably 2 to 6;Z′ is a C-terminal group; andb is 0 or 1.23.-. (canceled)4. The hydrophobic peptide and/or peptidomimetic according to claim 1 , wherein all or a portion of said aliphatic amino acids are arranged in an order of decreasing amino acid size in the direction from N- to C-terminus claim 1 , wherein the size of the aliphatic amino acids is defined as I=L>V>A>G.5. The hydrophobic peptide and/or peptidomimetic according to claim 1 , wherein the first N-terminal amino acid of said aliphatic amino acids is G claim 1 , V or A.6. (canceled)8. (canceled)9. The hydrophobic peptide and/or peptidomimetic according to claim 1 , wherein said N-terminal protecting group Z has the general formula —C(O)—R claim 1 , wherein R is selected from the group consisting of H claim 1 , unsubstituted or substituted alkyls claim 1 , and unsubstituted or substituted aryls claim 1 ,wherein R is preferably selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl and isobutyl.1011-. (canceled)12. The hydrophobic peptide and/or peptidomimetic ...

Подробнее
05-01-2017 дата публикации

MODIFIED BIOPOLYMERS AND METHODS OF PRODUCING AND USING THE SAME

Номер: US20170002098A1
Принадлежит:

Modified biopolymers, such as, charge-modified biopolymers, cross-linked biopolymers, and cross-linked, charge-modified biopolymers are provided along with methods of producing and using the same. 1. A method for producing a cross-linked , charge-modified biopolymer comprising:combining a biopolymer and at least one charge-modifying agent to form a homogenous reaction blend;reacting the biopolymer and the at least one charge-modifying agent in the homogenous reaction blend; andcross-linking the biopolymer in the homogeneous reaction blend to form a cross-linked, charge-modified biopolymer.2. The method of claim 1 , wherein the combining step further comprises combining a plasticizer and optionally a catalyst with the biopolymer and the at least one charge-modifying agent to form the homogenous reaction blend.3. The method of claim 1 , wherein the cross-linking step further comprises reacting the charge-modified biopolymer with at least one cross-linking agent claim 1 , optionally in the presence of an initiator.4. The method of claim 1 , wherein the reacting and cross-linking steps occur simultaneously.5. The method of any one of claim 1 , further comprising foaming the cross-linked claim 1 , charge-modified biopolymer.6. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer comprises a plurality of void spaces formed therein having an average diameter of about 0.1 to about 500 microns.7. The method of claim 1 , wherein the biopolymer comprises at least two different biopolymers claim 1 , optionally wherein one of the at least two different biopolymers is a charge-modified biopolymer.8. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer has a net positive charge or a net negative charge.9. The method of claim 1 , wherein the cross-linked claim 1 , charge-modified biopolymer is a polyampholyte.10. The method of claim 1 , wherein the combining step comprises melting blending the biopolymer and the at ...

Подробнее
05-01-2017 дата публикации

Methods for Purifying Polysaccharides and Pharmaceutical Compositions and Medical Devices Containing the Same

Номер: US20170002099A1
Принадлежит:

Methods for removing endotoxin from naturally occurring materials, such as polysaccharides (e.g., agarose and/or carrageenan) are described herein. Polysaccharides that are substantially free of endotoxins and uses thereof are also described. The polysaccharide materials can be isolated from microorganisms, multicellular organisms, such as, algae, plants, seaweed, etc. The method involves the use of acidic and basic solutions to hydrolyze the lipid-polysaccharide bond in endotoxins. Cleaving the fatty acid from the polysaccharide reduces the water-solubility of the fatty acid and enables its removal with an organic solvent such as ethanol. The polysaccharide component can also undergo acidic or basic hydrolysis due to the weak glycosidic bond between the sugar rings. 1. A method for isolating and purifying a naturally occurring agarose or derivative thereof produced from a biological source , the method comprising:(i) dispersing the agarose in one or more aliphatic alcohols to disrupt the bacterial wall to solubilize the lipid portion of endotoxins;(ii) removing the aliphatic alcohol to remove the lipid portion of the endotoxins and obtain the agarose or derivative thereof in solid form;(iii) dispersing the solid agarose or derivative thereof in a basic solution to hydrolyze lipid-inner core bonds of the endotoxins and solubilize the polysaccharide component of the endotoxins;(iv) washing the solution from step (iii) with an aliphatic alcohol to remove free lipids;(v) removing the basic solution in step (iii) to obtain the agarose or derivative thereof in solid form;(vi) dispersing the solid agarose or derivative thereof in an acidic solution to hydrolyze lipid-inner core bonds of the endotoxins not cleaved in step (iii);(vii) removing the acidic solution in step (vi) to obtain the agarose or derivative thereof in solid form;(viii) dispersing the solid agarose or derivative thereof from step (vii) in a second basic solution to further cleave lipid-inner core bonds ...

Подробнее
01-01-2015 дата публикации

INTERVENTIONAL MEDICAL DEVICE AND MANUFACTURING METHOD THEREOF

Номер: US20150004207A1

An interventional medical device and manufacturing method thereof, the interventional medical device comprising a stent body (); the stent body () is provided with a drug releasing structure on the surface, the drug in the drug releasing structure being a drug for inhibiting adventitial fibroblast proliferation. When the interventional medical device is implanted into a human body, the drug for inhibiting the adventitial fibroblast proliferation can be slowly released into vessel wall cells in contact with the stent body (), thus inhibiting the proliferation of the adventitial fibroblasts, promoting vascular compensatory expansion, and reducing the incidence rate of instent restenosis. 1. An interventional medical device comprising a stent body with a drug releasing structure on its surface , wherein the drug in said drug releasing structure is a drug for inhibiting adventitial fibroblast proliferation.2. The interventional medical device according to claim 1 , wherein said drug releasing structure is a dense mixed layer formed by a polymer and the drug for inhibiting adventitial fibroblast proliferation.3. The interventional medical device according to claim 2 , wherein said polymer includes polylactic acid claim 2 , polyethylene glycol claim 2 , styrene-butene copolymer claim 2 , polycaprolactone claim 2 , poly(butyl methacrylate) claim 2 , poly (ethyl methacrylate) claim 2 , polyvinyl ethyl acetate claim 2 , polyurethane claim 2 , polyvinyl pyrrolidone claim 2 , polyphosphorylcholine claim 2 , silk protein claim 2 , gelatin claim 2 , chitin and/or hyaluronic acid.4. The interventional medical device according to claim 1 , wherein said drug releasing structure is a microporous structure prepared on the surface of said stent body or a microporous coating structure formed on the surface of said stent body claim 1 , and the drug is loaded in said microporous structure or microporous coating structure.5. The interventional medical device according to claim 1 , wherein ...

Подробнее
20-01-2022 дата публикации

Systems and methods for minimally invasive delivery and in vivo creation of biomaterial structures

Номер: US20220015748A1
Принадлежит: Nextern Innovation LLC

Apparatus and associated methods relate to closure of a stoma with a structure continuously formed in vivo. In an illustrative example, a stoma closure tool (SCT) may include a drive module, a phase transition inducement module (PTIM), and a conduit that defines a lumen. A distal end of the conduit may, for example, be inserted through a first tissue and into a second tissue that together at least partially define a stoma. A flow rate of a fluid biomaterial through the lumen and discharged at the distal end of the conduit may, for example, be controlled by the drive module. A fluid to solid phase transition in the biomaterial may, for example, be controllably induced by the PTIM. Various embodiments may, for example, advantageously form a continuous structure extending directly across the stoma between a proximal anchor in the first tissue and a distal anchor in the second tissue.

Подробнее
20-01-2022 дата публикации

Compositions and methods for treating bone injury

Номер: US20220016162A1
Автор: Vaida Glatt
Принадлежит: University of Texas System

The disclosure relates to compositions and methods of treating, improving, and accelerating the healing of large segmental bone defects in a subject. The method comprises administering to a patient in need of treatment an effective amount of whole blood, sodium citrate, ecarin and BMP-2.

Подробнее
12-01-2017 дата публикации

COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE

Номер: US20170007407A1
Принадлежит:

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprising porous ceramic particles in a biodegradable polymer, and an oxysterol disposed in or on the compression resistant implant. Methods of making and use are further provided. 1. A compression resistant implant configured to fit at or near a bone defect to promote bone growth , the compression resistant implant comprising porous ceramic particles in an amount of about 30 wt % to about 99.5 wt % in a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % based on a total weight of the implant , and an oxysterol disposed in or on the compression resistant implant.2. An implant according to claim 1 , wherein the implant is not compressed any more than about 20% in any one direction for a period of at least about 30 days in vivo.3. An implant according to claim 1 , wherein (i) the porous ceramic particles are uniformly distributed throughout the implant; (ii) the oxysterol is uniformly distributed throughout the biodegradable polymer; and/or (iii) the oxysterol is uniformly distributed throughout the porous ceramic particles.4. An implant according to claim 1 , wherein the porous ceramic particles form a ceramic skeleton claim 1 , the skeleton having pores in the range of 1-10 mm in diameter claim 1 , and a total porosity of 50-98%.5. An implant according to claim 1 , wherein the implant comprises autograft claim 1 , allograft and/or xenograft bone particles.6. An implant according to claim 1 , wherein the biodegradable polymer comprises porcine-derived collagen claim 1 , human-derived collagen claim 1 , bovine-derived collagen claim 1 , piscine-derived collagen claim 1 , ovine-derived collagen claim 1 , recombinant collagen claim 1 , gelatin claim 1 , or combinations thereof.7. An implant according to claim 1 , wherein (i) the porous ceramic particles comprise bone powder claim 1 , demineralized bone ...

Подробнее
12-01-2017 дата публикации

Injectable silk fibroin foams and uses thereof

Номер: US20170007738A1
Принадлежит: TUFTS UNIVERSITY

The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein can be injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection). In some embodiments, the composition described herein comprises a compressed silk fibroin matrix, which can expand upon injection into the tissue and retain its original expanded volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation.

Подробнее
12-01-2017 дата публикации

HEMOSTATIC COMPOSITIONS AND METHODS

Номер: US20170007742A1
Принадлежит: STB, Ltd.

Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A composition for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic putty that is formed by combining a hemostatic material in an aqueous solution and drying under certain conditions to form a putty material that is capable of forming fibrin when in contact with an aqueous solution.2. The composition in claim 1 , wherein said composition is substantially non-adherent to latex gloves.3. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue the haemostatic putty of .4. A composition for treating wounded internal tissue in a mammal comprising at least one haemostatic material made by compressing powdered hemostatic components together with excipients to form shaped haemostatic materials.5. The composition of claim 4 , wherein said powdered hemostatic components are made from a single aqueous solution.6. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue the haemostatic composition of .7. The composition of claim 1 , wherein said hemostatic material consists essentially of a fibrinogen component and a fibrinogen activator.8. The composition of claim 1 , wherein said hemostatic material consists essentially of a fibrinogen component.9. The composition of claim 1 , wherein said hemostatic material consists essentially of a fibrinogen activator.10. The composition of claim 4 , wherein said hemostatic material consists essentially of a fibrinogen component and a fibrinogen activator.11. The composition of claim 4 ...

Подробнее
11-01-2018 дата публикации

BANDAGE HAVING HEMOSTATIC GAUZE AND METHOD THEREFOR

Номер: US20180008474A1
Автор: JAN JONATHAN
Принадлежит:

A bandage to control bleeding from an open wound has a hemostatic gauze. An absorbent pad is removably attached to the hemostatic gauze. 1. A bandage to control bleeding from an open wound comprising:a hemostatic gauze; andan absorbent pad removably attached to the hemostatic gauze.2. The bandage of claim 1 , comprising a water soluble adhesive applied to one of the hemostatic gauze or the absorbent pad to removably attach the hemostatic gauze to the absorbent pad.3. The bandage of claim 1 , wherein the hemostatic gauze is heat pressed to the absorbent pad to removably attach the hemostatic gauze to the absorbent pad.4. The bandage of claim 1 , wherein fibers of the hemostatic gauze are intertwined with fibers of the absorbent pad to removably attach the hemostatic gauze to the absorbent pad.5. The bandage of claim 1 , wherein the hemostatic gauze is a non-woven chitosan fabric.6. The bandage of claim 1 , comprising a strip of material claim 1 , wherein an interior side of the strip of material has an adhesive material formed thereon claim 1 , the hemostatic gauze attached to the interior side of the strip of material.7. The bandage of claim 1 , comprising a porous-polymer coating applied on the absorbent pad.8. The bandage of claim 1 , comprising an antiseptic solution applied on the absorbent pad.9. The bandage of claim 5 , wherein the non-woven chitosan fabric is a non-woven claim 5 , non-water soluable chitosan fabric which allows blood plasma to pass through and be absorbed by the absorbent pad claim 5 , while the non-woven claim 5 , non-water soluable chitosan fabric reacts with red blood cells to form a clot.10. A bandage to control bleeding from an open wound comprising:a non-woven chitosan fabric;an absorbent pad removably attached to the non-woven chitosan fabric; anda strip of material, wherein an interior side of the strip of material has an adhesive material formed thereon, the non-woven chitosan fabric attached to the interior side of the strip of ...

Подробнее
11-01-2018 дата публикации

HEMOSTATIC AGENT

Номер: US20180008560A1
Принадлежит:

The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula 2. A hemostatic agent as per Par. 1 , which differs in the fact that it is applied in the form of a 0.01-10% aqueous solution.3. A hemostatic agent as per Par. 2 , which differs in the fact that it is used for impregnation of hemostatic materials.4. A hemostatic agent as per Par. 3 , which differs in the fact that it is used for impregnation of suture materials.5. A hemostatic agent as per Par. 3 , which differs in the fact that it is used for impregnation of bandaging materials.6. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of a retraction cord.7. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of adhesive pastes.8. A hemostatic agent as per Par. 2 , which differs in the fact that it is used in the form of a spray.9. A hemostatic agent as per Par. 2 , which differs in the fact that it is used for inhalation.10. A hemostatic agent as per Par. 1 , which differs in the fact that it is used in the form of vaginal suppositories.11. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of rectal suppositories.12. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of a cream.13. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of a gel.14. A hemostatic agent as per Par. 1 , which differs in the fact that it is applied using chips that provide slow release of the drug.15. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of eye drops.16. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of eye ointments.17. A hemostatic agent as per Par. 1 , which differs in the fact that it is used as part of a lubricant applied onto the surface of the catheter.18. A ...

Подробнее